Free Research Report Download:
The Cancer Market Outlook To 2014
Free Pharmaceutical Market Research Reports
Corporate & Fiscal
Pharmaceutical Events & Conferences
Terms & Conditions
What does the future hold for drug delivery technologies? Visiongain's report shows you potential revenues and other trends, with data, forecasts and discussions.
This decade, many commercial opportunities for improved drug delivery exist. You discover sales predictions to 2022 at world market, submarket, application and national level.
In particular, our report forecasts six submarkets to 2022, showing you potential revenues:
• Oral delivery
• Inhaled delivery
• Transdermal delivery
• Ocular delivery
• Nasal delivery
• Implants for drug delivery.
The study discusses 3M, Catalent, Alkermes, Generex Biotechnology, pSivida and many other technology providers, letting you assess outlooks for the industry and market.
How will biological drugs using the technologies perform from 2012? You find overall revenues from nine pharmaceutical areas predicted to 2022:
• Monoclonal antibodies
• G-CSF agents
• Recombinant coagulation factors
• Other therapeutic proteins
• Biosimilars and related agents
Our investigation gives you business research and analysis with many forecasts.
Where is drug delivery heading? Technologies and applications giving improved clinical efficacy, patient convenience and treatment compliance will achieve success.
Drug delivery R&D is promising. Suppliers and users of the technology will benefit. Our calculations show you the potential for expanded revenues to 2022.
Which areas of pharma will benefit most? Drug delivery technologies offer many opportunities for pharma line extensions and product lifecycle management, benefiting a wide range of drugs. Biologicals and vaccines will profit especially. You see how.
In our analysis, the drug delivery technology industry will achieve high revenue growth from 2012 to 2022. In particular, greater use of injectable drugs and vaccines worldwide will stimulate demand for innovative delivery systems.
We find wide scope for novel and improved drug delivery from 2012 onwards, seeing many sales opportunities for products and services there. Our report explains.
Visiongain's study provides data, analysis and opinion aiming to benefit your research, calculations and presentations. You find answers in our work.
Revenue forecasts, market shares, developmental trends and discussions
In our report you find revenue forecasting, growth rates and market shares. Also, you have qualitative analyses (SWOT and STEP) and discussion of technologies, existing and in development. You receive 90 tables and charts and four research interviews.
Advantages of Drug Delivery Technologies: Commercial Prospects 2012-2022 for your work
In particular, this study gives you the following knowledge:
• Find potential revenues to 2022 for the world market and submarkets
• See market forecasting to 2022 for US, Japan, EU5, China and India
• Receive forecasts to 2022 for drug classes using the systems
• Assess leading companies, discovering activities and outlooks
• Review technological developments, assessing trends and prospects
• Investigate competition and opportunities influencing revenues
• Find out what will stimulate and restrain the industry and market
• View opinions from our survey, receiving four interviews.
There, you find an original mix of quantitative and qualitative analyses with independent predictions. Receive data that only our report contains, harnessing our pharma knowledge.
Through our analytical methods we keep you informed about commercial trends and prospects. By getting our report now, you could find that information before your competitors.
3M Drug Delivery Systems
Applied Pharma Research (APR)
Axcan Intermediate Holdings
Bausch & Lomb
Biological E. Limited
Catalent Pharma Solutions
Centocor Ortho Biotech
Cima Labs (Cephalon)
Department of Health and Human Services (US)
Dr. Reddy's Laboratories
E. Merck KG
E. R. Squibb & Sons
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Genentech (now part of Roche)
Generex Biotechnology Corporation
Hisamitsu Pharmaceutical Co.
Human Genome Sciences
Johnson & Johnson (J&J)
Leiras OY (Nycomed)
LG Life Sciences
Merck & Co.
National Institute for Health and Clinical Excellence (NICE, UK)
Otsuka Pharmaceuticals Co
Research Foundation for Microbial Diseases of Osaka University (BIKEN)
Sandoz (part of Novartis)
Sanofi (formerly sanofi-aventis)
Sanofi Pasteur MSD
Schering-Plough Corporation (now part of Merck & Co.)
Sosei Group Corp.
Statens Serum Institut
Team Consulting Limited
Teva Pharmaceutical Industries
The Blackstone Group
University of Copenhagen, Denmark
Wyeth (now a part of Pfizer Inc.)
Zhejiang CONBA Pharmaceutical Co.